Pharmaceutical Products
Desonate® Gel is a low potency topical steroid formulated in a proprietary water-based Hydrogel vehicle. It is the only treatment for mild-to-moderate atopic dermatitis, an inflammatory skin disorder, indicated for patients as young as 3 months that offers the benefits of Hydrogel technology.
The most frequent adverse events included headache (2%), application site burning (1%), rash (1%), and pruritus (<1%). Desonate Gel is contraindicated in those patients with a history of hypersensitivity to any of the components.
If irritation develops, Desonate Gel should be discontinued and appropriate therapy instituted. Unless directed by the physician, the treated skin area should not be bandaged so as to be occlusive. Systemic absorption of topical corticosteroids, including Desonate Gel, has produced HPA axis suppression for which pediatric patients are more susceptible.
Desonate Gel is not indicated for diaper dermatitis. Please see full prescribing information for Desonate Gel.
NeoBenz® Micro is the only prescription benzoyl peroxide medication formulated with the MICROSPONGE® delivery system for the treatment of mild to moderate acne vulgaris. This unique formulation allows for a gradual release of benzoyl peroxide over time, effectively treating acne with very low irritation. NeoBenz Micro products are available in a 7% benzoyl peroxide wash, a 5.5% cream, and 5.5% single dose (SD).
As with all benzoyl peroxide products, NeoBenz Micro should not be used in patients who have shown hypersensitivity to benzoyl peroxide or to any of the other ingredients. Allergic contact dermatitis and dryness have been reported with topical benzoyl peroxide therapy. Please see full prescribing information for NeoBenz Micro.
MICROSPONGE® is a registered trademark of AMCOL International Corporation.
VANIQA® is the only prescription product available in the U.S. for the reduction of growth of unwanted facial hair in women. VANIQA works during the growth phase of the hair cycle by blocking an enzyme that is necessary for hair growth. VANIQA does not remove facial hair; instead, it is designed to reduce the rate of growth of facial hair and increase the interval between periods of hair removal when used together with traditional hair removal methods such as shaving, waxing and tweezing. Clinical trials have shown results from the use of VANIQA in four to eight weeks from initial application, with continued improvement over time.
If no improvement is seen after 6 months of use, VANIQA should be discontinued. The most frequent adverse events related to treatment with VANIQA were skin related adverse events. Individual results may vary. Please see full prescribing information for VANIQA.
EpiQuin® Micro is a topical 4% hydroquinone product indicated for the treatment of hyperpigmentation, a condition that results in heavily pigmented or dark areas of the skin. EpiQuin Micro is the only prescription hydroquinone product available with the MICROSPONGE® delivery system. The unique formulation allows for a gradual release of the active ingredient, prolonging exposure to the treatment while minimizing skin irritation.
EpiQuin Micro should be tested for skin sensitivity prior to use. Excessive inflammatory responses are contraindications to further use, while minor redness is not. Hydroquinone may produce unwanted effects if not used as directed. Please see full prescribing information for EpiQuin Micro. MICROSPONGE® is a registered trademark of AMCOL International Corporation.